<DOC>
	<DOCNO>NCT02371226</DOCNO>
	<brief_summary>AGT-181 fusion protein contain alpha-L-Iduronidase intend deliver enzyme peripherally brain , administer intravenously . This study safety dose range study obtain safety exposure data , well information biological activity investigational drug .</brief_summary>
	<brief_title>Safety Dose Ranging Study Insulin Receptor MAb-IDUA Fusion Protein Patients With MPS I</brief_title>
	<detailed_description />
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis I</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male age 18 year old Diagnosis MPS I ( document fibroblast leukocyte IDUA enzyme activity level le 10 % low limit normal range measure laboratory ) Voluntary write consent patient legally responsible representative All woman childbearing potential sexually mature male must advise use medically accept method contraception throughout study . Negative pregnancy test ( female ) Must receive ERT least 6 week prior AGT181 treatment Must elevate urinary GAGs ERT receive prior 3 month Refusal complete baseline evaluation . Any medical condition circumstance may significantly interfere study compliance Receipt investigational drug within prior 90 day History diabetes mellitus hypoglycemia Clinically significant spinal cord compression , evidence cervical instability . Known hypersensitivity alphaLiduronidase component AGT181 . Known nonresponsive standard ERT treatment . Previously successful ( engraft ) hematopoietic stem cell transplantation result normalization urinary GAGs . Contraindication lumbar puncture</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>MPS I</keyword>
</DOC>